Emergent Biosolutions, Inc. (EBS) is a publicly traded Healthcare sector company. As of May 21, 2026, EBS trades at $8.18 with a market cap of $419.48M and a P/E ratio of -58.21. EBS moved +1.30% today. Year to date, EBS is -36.58%; over the trailing twelve months it is +17.44%. Its 52-week range spans $4.02 to $14.06. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces EBS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Emergent BioSolutions Q1 Revenue Beats Guidance as Debt Drops 22%: Emergent BioSolutions reported Q1 revenue of $156 million, beat guidance, and cut net debt 22% by repaying $110 million and adding a $75 million term loan. International MCM now covers 37% of the segment, with 45%–47% margin outlook, and the prior large international order is nonrecurring.
| Metric | Value |
|---|---|
| Price | $8.18 |
| Market Cap | $419.48M |
| P/E Ratio | -58.21 |
| EPS | $-0.14 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.06 |
| 52-Week Low | $4.02 |
| Volume | 458 |
| Avg Volume | 0 |
| Revenue (TTM) | $676.80M |
| Net Income | $-8.60M |
| Gross Margin | 54.24% |
1 analysts cover EBS: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.